Ingevity Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Ingevity ont diminué à un taux annuel moyen de -58.4%, tandis que le secteur Chemicals a vu ses bénéfices augmenter de en baisse à 4% par an. Les revenus ont augmenté de en baisse à un taux moyen de 3.1% par an.
Informations clés
-58.42%
Taux de croissance des bénéfices
-58.03%
Taux de croissance du BPA
| Chemicals Croissance de l'industrie | 12.93% |
| Taux de croissance des recettes | -3.13% |
| Rendement des fonds propres | -401.03% |
| Marge nette | -13.25% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Seeking Alpha • May 19
Ingevity - Shrinking To Grow
Summary Ingevity is pursuing a shrink-to-grow strategy, divesting non-core assets to boost focus and margins. Recent asset sales fetched modest prices, following significant impairment charges, but have not materially impacted earnings. Ingevity´s leverage is gradually declining, with 2026 guidance targeting $4.70–$5.20 EPS and $370–$395 million adjusted EBITDA. I remain cautiously optimistic, seeing potential for re-rating if further simplification or a performance materials spin-off occurs. Read the full article on Seeking Alpha
Mise à jour du récit • May 14
NGVT: Future P/E Will Reward Margin Strength Despite Recent Impairment Charge
Analysts have raised Ingevity's price target from $80.50 to $85.50, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe more accurately reflect the stock's risk and earnings profile. What's in the News Ingevity reaffirmed earnings guidance for full year 2026, with expected net sales in a range of $1.05b to $1.15b (company guidance).Mise à jour du récit • Apr 28
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.Mise à jour du récit • Apr 11
NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.Mise à jour du récit • Mar 28
NGVT: Higher P/E Will Rely On Future Margin Delivery
Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.Mise à jour du récit • Mar 13
NGVT: Higher P/E Outlook Will Depend On Margin Execution
Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.Mise à jour du récit • Feb 24
NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook
Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.Mise à jour du récit • Feb 09
NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook
Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.Mise à jour du récit • Jan 26
NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook
Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.Mise à jour du récit • Jan 10
NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook
Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.Mise à jour du récit • Dec 25
NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset
Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.Mise à jour du récit • Dec 10
NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential
Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.Article d’analyse • Sep 30
Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
While Ingevity Corporation ( NYSE:NGVT ) might not have the largest market cap around , it received a lot of attention...Article d’analyse • Sep 06
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Mise à jour du récit • Sep 05
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.Mise à jour du récit • Aug 06
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.Article d’analyse • Jun 27
Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Ingevity is US$71.30 based on 2 Stage Free Cash Flow to Equity Ingevity's...Article d’analyse • May 28
Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
Those holding Ingevity Corporation ( NYSE:NGVT ) shares would be relieved that the share price has rebounded 33% in the...Nouveau récit • May 27
Premium Markets Will Secure Long Term Value
Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.Article d’analyse • Apr 05
Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge
Ingevity Corporation ( NYSE:NGVT ) shares have had a horrible month, losing 32% after a relatively good period...Article d’analyse • Feb 20
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Article d’analyse • Jan 16
Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights Ingevity's estimated fair value is US$82.84 based on 2 Stage Free Cash Flow to Equity Ingevity is...Article d’analyse • Nov 07
What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You
Ingevity Corporation ( NYSE:NGVT ) shareholders have had their patience rewarded with a 32% share price jump in the...Article d’analyse • Oct 13
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Sep 08
Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares
When you see that almost half of the companies in the Chemicals industry in the United States have price-to-sales...Seeking Alpha • Aug 27
Ingevity: The Risk-Reward Ratio Is Still Unfavorable
Summary Ingevity, once considered a growth story, turned out to be a classic example of market cycles. While Road Technology and Performance Materials performed reasonably well in the first half of 2024, the Industrial Specialties segment dragged down revenue and net income. Given the company's significant debt burden, risk-averse investors should seek safer options within the chemical industry. Read the full article on Seeking AlphaArticle d’analyse • Aug 03
Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a notable change in appetite for Ingevity Corporation ( NYSE:NGVT ) shares in the week since its quarterly...Article d’analyse • Jul 13
Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Jun 14
Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it received a lot of attention from a...Article d’analyse • Apr 18
Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?
Key Insights Ingevity's estimated fair value is US$78.59 based on 2 Stage Free Cash Flow to Equity Current share price...Article d’analyse • Mar 22
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Jan 23
What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it saw a double-digit share price rise of over...Article d’analyse • Jan 04
Ingevity Corporation (NYSE:NGVT) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 12.6x Ingevity Corporation ( NYSE:NGVT ) may be sending bullish signals at...Article d’analyse • Nov 10
These Analysts Just Made An Incredible Downgrade To Their Ingevity Corporation (NYSE:NGVT) EPS Forecasts
The latest analyst coverage could presage a bad day for Ingevity Corporation ( NYSE:NGVT ), with the analysts making...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Ingevity gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 1,178 | -156 | 170 | 28 |
| 31 Dec 25 | 1,168 | -150 | 171 | 28 |
| 30 Sep 25 | 1,382 | -361 | 177 | 31 |
| 30 Jun 25 | 1,383 | -354 | 171 | 30 |
| 31 Mar 25 | 1,108 | -36 | 152 | 25 |
| 31 Dec 24 | 1,200 | -121 | 158 | 25 |
| 30 Sep 24 | 1,309 | -258 | 163 | 25 |
| 30 Jun 24 | 1,421 | -280 | 165 | 27 |
| 31 Mar 24 | 1,640 | -112 | 183 | 30 |
| 31 Dec 23 | 1,216 | 106 | 162 | 25 |
| 30 Sep 23 | 1,704 | 127 | 196 | 32 |
| 30 Jun 23 | 1,740 | 177 | 210 | 32 |
| 31 Mar 23 | 1,678 | 202 | 207 | 32 |
| 31 Dec 22 | 1,668 | 212 | 198 | 30 |
| 30 Sep 22 | 1,621 | 225 | 191 | 30 |
| 30 Jun 22 | 1,516 | 146 | 181 | 29 |
| 31 Mar 22 | 1,454 | 130 | 179 | 27 |
| 31 Dec 21 | 1,392 | 118 | 179 | 26 |
| 30 Sep 21 | 1,381 | 135 | 169 | 25 |
| 30 Jun 21 | 1,336 | 209 | 160 | 24 |
| 31 Mar 21 | 1,248 | 185 | 151 | 23 |
| 31 Dec 20 | 1,216 | 181 | 150 | 23 |
| 30 Sep 20 | 1,194 | 180 | 153 | 22 |
| 30 Jun 20 | 1,222 | 170 | 159 | 21 |
| 31 Mar 20 | 1,304 | 206 | 163 | 21 |
| 31 Dec 19 | 1,293 | 184 | 163 | 20 |
| 30 Sep 19 | 1,268 | 182 | 158 | 20 |
| 30 Jun 19 | 1,219 | 171 | 152 | 21 |
| 31 Mar 19 | 1,175 | 161 | 145 | 22 |
| 31 Dec 18 | 1,134 | 169 | 133 | 22 |
| 30 Sep 18 | 1,085 | 169 | 125 | 22 |
| 30 Jun 18 | 1,037 | 153 | 116 | 21 |
| 31 Mar 18 | 989 | 138 | 107 | 20 |
| 31 Dec 17 | 972 | 127 | 107 | 20 |
| 30 Sep 17 | 954 | 94 | 104 | 19 |
| 30 Jun 17 | 942 | 53 | 103 | 18 |
| 31 Mar 17 | 927 | 45 | 100 | 18 |
| 31 Dec 16 | 908 | 35 | 96 | 18 |
| 30 Sep 16 | 898 | 34 | 93 | 13 |
| 30 Jun 16 | 902 | 64 | 95 | 9 |
| 31 Mar 16 | 919 | 66 | 105 | 5 |
| 31 Dec 15 | 958 | 80 | 93 | 17 |
| 30 Sep 15 | 999 | 99 | 107 | 8 |
| 30 Jun 15 | 1,025 | 115 | 108 | 8 |
Des revenus de qualité: NGVT n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: NGVT n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: NGVT n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 58.4% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de NGVT au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: NGVT n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Chemicals ( -1.4% ).
Rendement des fonds propres
ROE élevé: NGVT a un retour sur capitaux propres négatif ( -401.03% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/25 15:35 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Ingevity Corporation est couverte par 8 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Paretosh Misra | Berenberg |
| John McNulty | BMO Capital Markets Equity Research |
| Jonathan Tanwanteng | CJS Securities, Inc. |